Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)

August 30, 2023 07:17 AM EDTUpdated 12:48 PM

Updated: Novo Nordisk bags new obesity target in latest biotech acquisition, inks R&D deal with spinout

Amber Tong

Novo Nordisk has found another obesity-focused biotech to buy as it looks to build on the success of its blockbuster semaglutide franchise. And this time …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Novo Nordisk bags new obesity target in latest biotech acquisition, inks R&D deal with spinout

Amber Tong

Sign up to read this article for free.

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Up­dat­ed: No­vo Nordisk bags new obe­si­ty tar­get in lat­est biotech ac­qui­si­tion, inks R&D deal with spin­out

Amber Tong

Sign up to read this article for free.

more like this

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Updated: Novo Nordisk bags new obesity target in latest biotech acquisition, inks R&D deal with spinout

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial